sFas和sFasL在乳腺癌新辅助化疗过程中的临床意义

发布时间：2018-01-18 14:04

本文关键词：sFas和sFasL在乳腺癌新辅助化疗过程中的临床意义　出处：《浙江大学》2015年硕士论文　论文类型：学位论文

【摘要】：目的：通过检测乳腺癌患者新辅助前、后及术后血清sFas和sFasL水平,对比其变化趋势,初步探讨sFas来源及临床指导意义,试图为乳腺癌临床诊疗方案的制定提供更简便、更客观的临床依据。方法：1.前瞻性筛选患者17名,条件：浸润性导管癌、符合前辅助化疗适应症、年龄30-65岁,女性；对比组为15名健康女性,条件：对已排除高血压、糖尿病等慢性疾病,同时排除有血液疾病病史或其他恶性肿瘤的患者。2.采用酶联免疫吸附法(ELISA)检测乳腺癌患者及健康女性血清中sfas和sFasL含量。3.采用GraphPad.Prism.v5.0for windows统计软件进行分析。结果：1.sFas在新辅助化疗前乳腺癌患者血清中含量低(39.58±17.38),与正常人群(20.56±6.807)相比无显著统计学差异(p=0.2122)；在新辅助化疗后患者血清中浓度增高(302.8±72.86),与新辅助化疗前及正常对照组均存在显著统计学差异(p0.05)；患者术后血清中浓度较新辅助后(即术前)无显著统计学差异(p=0.4259)。2.对于雌激素受体阳性乳腺癌患者,新辅助化疗有效组(CR+PR)的sFas血清含量(前20.60±9.974、后175.4±59.15)较无效患者(SD+PD)两组中患者sFas血清含量(前19.82-9.143、后511.6±381.6)明显增高,存在明显差异(p0.05)。3.sFasL在新辅助前后、术后、正常对照组之间均无统计学差异(p=0.1160、p=0.2530、p=0.5845)。结论：1.患者血清中sFas在新辅助化疗后显著上升。2.sFas可以对于ER阳性乳腺癌患者,通过观察其血清浓度变化,早期预测新辅助化疗疗效。3.sFasL在患者血清中治疗前后均无明显变化。
[Abstract]:Objective: to study the origin and clinical significance of sFas and sFasL in patients with breast cancer by detecting the levels of serum sFas and sFasL before, after and after neoadjuvant operation. This paper attempts to provide a more simple and objective clinical basis for the clinical diagnosis and treatment of breast cancer. Methods 17 patients with invasive ductal carcinoma were selected prospectively. The patients were in accordance with the indications of preadjuvant chemotherapy, aged 30-65 years, female; The control group consisted of 15 healthy women. The condition was that hypertension, diabetes and other chronic diseases were excluded. Exclusion of patients with a history of blood disease or other malignant neoplasms .2.Enzyme-linked immunosorbent assay (Elisa). The levels of sfas and sFasL in serum of breast cancer patients and healthy women were measured. 3. GraphPad.Prism.v5.0for was used. Windows statistical software was used to analyze. Results 1. The serum level of SFAS in breast cancer patients before neoadjuvant chemotherapy was 39.58 卤17.38). There was no significant difference between 0.2122 and 20.56 卤6.807 in normal population. After neoadjuvant chemotherapy, the serum concentration increased by 302.8 卤72.86, which was significantly different from that before neoadjuvant chemotherapy and normal control group (P 0.05). There was no significant difference in serum concentration between the patients after operation and that after neoadjuvant (i.e., preoperative). For breast cancer patients with estrogen receptor positive, there was no significant difference. The serum level of sFas in neo-adjuvant chemotherapy group was 20.60 卤9.974. The serum levels of sFas in the latter 175.4 卤59.15 were significantly higher than those in the ineffective group (19.82-9.143, 511.6 卤381.6). There was significant difference between the two groups before and after the neo-adjuvant operation, and there was no significant difference between the normal control group and the normal control group before and after neoadjuvant operation. (P = 0.5845). Conclusion: 1. The serum levels of sFas in patients with ER positive breast cancer were significantly increased after neoadjuvant chemotherapy. 2. SFAS could be used to observe the changes of serum concentration in patients with ER positive breast cancer. Early prediction of neoadjuvant chemotherapeutic efficacy. 3. SFasL had no significant change in serum before and after treatment.
【学位授予单位】：浙江大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R737.9

【参考文献】